Home Newsfeeds Old Second Bancorp Q3 EPS $0.43 Up From $0.29 YoY

Old Second Bancorp Q3 EPS $0.43 Up From $0.29 YoY

Old Second Bancorp (NASDAQ:OSBC) reported quarterly earnings of $0.43 per share. This is a 48.28 percent increase over earnings of $0.29 per share from the same period last year.

byMichael Horton

October 26, 2022

1 minute read

Old Second Bancorp (NASDAQ:OSBC) reported quarterly earnings of $0.43 per share. This is a 48.28 percent increase over earnings of $0.29 per share from the same period last year.

Lion Electric Announces Launch Of Overnight Marketed Public Offering Of Units, No Terms Disclosed

By Michael Horton

December 12, 5:23 PM

The Lion Electric Company (NYSE:LEV) (TSX:LEV) ("Lion" or the "Company"), a leading manufacturer of all-electric medium and heavy-duty urban vehicles, today announced the launch of a marketed

LEV

Here’s How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years

By Benzinga Insights

October 21, 1:55 PM

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 7.45% on an annualized basis producing an average annual return of 14.87%. Currently, Gilead Sciences has a market capitalization of $84.95 billion.

GILD

Goldman Sachs Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $25

By Benzinga Newsdesk

December 1, 6:35 AM

Goldman Sachs analyst Corinne Jenkins initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Buy rating and announces Price Target of $25.

ACRS

Walgreens Likely To Report Lower Q1 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

By Avi Kapoor

January 3, 11:21 AM

Walgreens Boots Alliance, Inc. (NASDAQ: WBA) is projected to release financial results for its fiscal 2024 first quarter, before the opening bell on Jan. 4, 2023.

WBA

Old Second Bancorp Q3 EPS $0.43 Up From $0.29 YoY

Related Posts

Lion Electric Announces Launch Of Overnight Marketed Public Offering Of Units, No Terms Disclosed

Here’s How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years

Goldman Sachs Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $25

Walgreens Likely To Report Lower Q1 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call